Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206414 · ClinicalTrials.gov registry record · Phase 2
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
A Phase 2 study, sponsored by Baylor Breast Care Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00206414 is a Phase 2 study that was terminated before completion, run by Baylor Breast Care Center. The registered enrollment target is 15 participants.
The verdict
NCT00206414, a Phase 2 study, was terminated before completion, sponsored by Baylor Breast Care Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The investigators want to know if combining Arimidex and Faslodex with Iressa will be an effective treatment for breast cancer. They also want to know, using special tests on the tumor, the changes that occur with the treatment so they can try to improve their treatment for breast cancer in the future.
Interventions
- DRUG Iressa Day 1 given with Arimidex and Faslodex
- DRUG Iressa Day 21 given with Arimidex and Faslodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206414
The ClinicalTrials.gov registry entry for NCT00206414 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Breast Care Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Iressa Day 1 given with Arimidex and Faslodex is the first listed.
NCT00206414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206414 about?
NCT00206414 is a clinical study titled "Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer". The investigators want to know if combining Arimidex and Faslodex with Iressa will be an effective treatment for breast cancer. They also want to know, using special tests on the tumor, the changes that occur with the treatment so they can try to improve their treatment for breast cancer in the futu...
What is the current status of trial NCT00206414?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2003-01. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00206414?
The interventions under investigation include: Iressa Day 1 given with Arimidex and Faslodex (DRUG), Iressa Day 21 given with Arimidex and Faslodex (DRUG).
Who is sponsoring clinical trial NCT00206414?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.